» Articles » PMID: 39769374

Revolutionizing Neuroimmunology: Unraveling Immune Dynamics and Therapeutic Innovations in CNS Disorders

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2025 Jan 8
PMID 39769374
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroimmunology is reshaping the understanding of the central nervous system (CNS), revealing it as an active immune organ rather than an isolated structure. This review delves into the unprecedented discoveries transforming the field, including the emerging roles of microglia, astrocytes, and the blood-brain barrier (BBB) in orchestrating neuroimmune dynamics. Highlighting their dual roles in both repair and disease progression, we uncover how these elements contribute to the intricate pathophysiology of neurodegenerative diseases, cerebrovascular conditions, and CNS tumors. Novel insights into microglial priming, astrocytic cytokine networks, and meningeal lymphatics challenge the conventional paradigms of immune privilege, offering fresh perspectives on disease mechanisms. This work introduces groundbreaking therapeutic innovations, from precision immunotherapies to the controlled modulation of the BBB using nanotechnology and focused ultrasound. Moreover, we explore the fusion of immune modulation with neuromodulatory technologies, underscoring new frontiers for personalized medicine in previously intractable diseases. By synthesizing these advancements, we propose a transformative framework that integrates cutting-edge research with clinical translation, charting a bold path toward redefining CNS disease management in the era of precision neuroimmunology.

References
1.
Sanjay , Sharma A, Lee H . Role of Phytoconstituents as PPAR Agonists: Implications for Neurodegenerative Disorders. Biomedicines. 2021; 9(12). PMC: 8698906. DOI: 10.3390/biomedicines9121914. View

2.
Farrer T, Moore J, Chase M, Gale S, Hedges D . Infectious Disease as a Modifiable Risk Factor for Dementia: A Narrative Review. Pathogens. 2024; 13(11). PMC: 11597442. DOI: 10.3390/pathogens13110974. View

3.
Bhardwaj S, Kesari K, Rachamalla M, Mani S, Ashraf G, Jha S . CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics. J Adv Res. 2022; 40:207-221. PMC: 9481950. DOI: 10.1016/j.jare.2021.07.001. View

4.
Fock E, Parnova R . Mechanisms of Blood-Brain Barrier Protection by Microbiota-Derived Short-Chain Fatty Acids. Cells. 2023; 12(4). PMC: 9954192. DOI: 10.3390/cells12040657. View

5.
Howlett-Prieto Q, Feng X, Kramer J, Kramer K, Houston T, Reder A . Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis. Mult Scler. 2021; 27(14):2170-2179. DOI: 10.1177/13524585211003301. View